AKBANasdaqPharmaceutical PreparationsFiscal year ends December 31
Akebia Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$0.68+0.01 (+1.51%)
Close on Oct 19, 2026
- Market cap
- $183.36M
- P/E (TTM)
- –
- Dividend yield
- –
Akebia Therapeutics, Inc. revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product revenue, net | $209.84M | $223.53M | $227.33M | $217.41M | $196.21M | $176.96M | $152.18M | $161.04M | $165.57M | $166.60M | $170.30M | $167.35M | 95.8% | +6.9% |
| Auryxia | $152.26M | $173.98M | $181.54M | $177.78M | $170.90M | $164.93M | $152.18M | – | – | – | – | – | 69.5% | -10.9% |
| Vafseo | $57.58M | $49.56M | $45.79M | $39.64M | $25.31M | $12.03M | $0 | – | – | – | – | – | 26.3% | +127.5% |
| License, collaboration and other revenue | $9.22M | $8.87M | $8.86M | $7.66M | $7.52M | $7.95M | $8.00M | $8.84M | $8.93M | $20.62M | $24.32M | $26.86M | 4.2% | +22.7% |
By region
From the segment and revenue-disaggregation notes of Akebia Therapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.